Trial Profile
A Phase I Study of the CDK4/6 Inhibitor PD-0332991, 5-Fluorouracil, and Oxaliplatin in Patients With Advanced Solid Tumor Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Oxaliplatin (Primary) ; Palbociclib (Primary) ; Folinic acid
- Indications Solid tumours
- Focus Adverse reactions
- 02 Mar 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 02 Mar 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 08 Oct 2019 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019.